These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 11402633)

  • 1. The pharmacokinetics of colistin in patients with cystic fibrosis.
    Reed MD; Stern RC; O'Riordan MA; Blumer JL
    J Clin Pharmacol; 2001 Jun; 41(6):645-54. PubMed ID: 11402633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis.
    Li J; Coulthard K; Milne R; Nation RL; Conway S; Peckham D; Etherington C; Turnidge J
    J Antimicrob Chemother; 2003 Dec; 52(6):987-92. PubMed ID: 14585859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of colistin after nebulization or intravenous administration of colistin methanesulphonate (Colimycin®) to cystic fibrosis patients.
    Magréault S; Mankikian J; Marchand S; Diot P; Couet W; Flament T; Grégoire N
    J Cyst Fibros; 2020 May; 19(3):421-426. PubMed ID: 31501050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosing guidance for intravenous colistin in critically-ill patients.
    Nation RL; Garonzik SM; Thamlikitkul V; Giamarellos-Bourboulis EJ; Forrest A; Paterson DL; Li J; Silveira FP
    Clin Infect Dis; 2017 Mar; 64(5):565-571. PubMed ID: 28011614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steady-state pharmacokinetic and pharmacodynamic profiling of colistin in critically ill patients with multi-drug-resistant gram-negative bacterial infections, along with differences in clinical, microbiological and safety outcome.
    Ram K; Sheikh S; Bhati RK; Tripathi CD; Suri JC; Meshram GG
    Basic Clin Pharmacol Toxicol; 2021 Jan; 128(1):128-140. PubMed ID: 33245629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration.
    Imberti R; Cusato M; Villani P; Carnevale L; Iotti GA; Langer M; Regazzi M
    Chest; 2010 Dec; 138(6):1333-9. PubMed ID: 20558557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis.
    Ratjen F; Rietschel E; Kasel D; Schwiertz R; Starke K; Beier H; van Koningsbruggen S; Grasemann H
    J Antimicrob Chemother; 2006 Feb; 57(2):306-11. PubMed ID: 16396919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale.
    Grégoire N; Mimoz O; Mégarbane B; Comets E; Chatelier D; Lasocki S; Gauzit R; Balayn D; Gobin P; Marchand S; Couet W
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7324-30. PubMed ID: 25267662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-performance liquid chromatographic method for the determination of colistin in serum.
    Le Brun PP; de Graaf AI; Vinks AA
    Ther Drug Monit; 2000 Oct; 22(5):589-93. PubMed ID: 11034265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacokinetics of Intravenous Colistin in Pediatric Patients: Implications for the Selection of Dosage Regimens.
    Ooi MH; Ngu SJ; Chor YK; Li J; Landersdorfer CB; Nation RL
    Clin Infect Dis; 2019 Nov; 69(11):1962-1968. PubMed ID: 30722017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic Characteristics and Limited Sampling Strategies for Therapeutic Drug Monitoring of Colistin in Patients With Multidrug-Resistant Gram-Negative Bacterial Infections.
    Kim EJ; Oh J; Lee K; Yu KS; Chung JY; Hwang JH; Nam EY; Kim HS; Kim M; Park JS; Song KH; Kim ES; Song J; Kim HB
    Ther Drug Monit; 2019 Feb; 41(1):102-106. PubMed ID: 30299430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study.
    Markou N; Markantonis SL; Dimitrakis E; Panidis D; Boutzouka E; Karatzas S; Rafailidis P; Apostolakos H; Baltopoulos G
    Clin Ther; 2008 Jan; 30(1):143-51. PubMed ID: 18343250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of Colistin Following a Single Dose of Intravenous Colistimethate Sodium in Critically Ill Neonates.
    Nakwan N; Usaha S; Chokephaibulkit K; Villani P; Regazzi M; Imberti R
    Pediatr Infect Dis J; 2016 Nov; 35(11):1211-1214. PubMed ID: 27276179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis.
    Bates RD; Nahata MC; Jones JW; McCoy K; Young G; Cox S; Barson WJ
    Chest; 1997 Nov; 112(5):1208-13. PubMed ID: 9367459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic/Toxicodynamic Analysis of Colistin-Associated Acute Kidney Injury in Critically Ill Patients.
    Forrest A; Garonzik SM; Thamlikitkul V; Giamarellos-Bourboulis EJ; Paterson DL; Li J; Silveira FP; Nation RL
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28893780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients.
    Karaiskos I; Friberg LE; Pontikis K; Ioannidis K; Tsagkari V; Galani L; Kostakou E; Baziaka F; Paskalis C; Koutsoukou A; Giamarellou H
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7240-8. PubMed ID: 26369974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single- and multiple-dose pharmacokinetics and total removal of colistin in critically ill patients with acute kidney injury undergoing prolonged intermittent renal replacement therapy.
    Schmidt JJ; Strunk AK; David S; Bode-Böger SM; Martens-Lobenhoffer J; Knitsch W; Scherneck S; Welte T; Kielstein JT
    J Antimicrob Chemother; 2019 Apr; 74(4):997-1002. PubMed ID: 30624668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin.
    Crass RL; Rutter WC; Burgess DR; Martin CA; Burgess DS
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration.
    Yapa SWS; Li J; Patel K; Wilson JW; Dooley MJ; George J; Clark D; Poole S; Williams E; Porter CJ; Nation RL; McIntosh MP
    Antimicrob Agents Chemother; 2014 May; 58(5):2570-9. PubMed ID: 24550334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of colistin plasma levels on the clinical outcome of patients with infections caused by extremely drug-resistant Pseudomonas aeruginosa.
    Sorlí L; Luque S; Segura C; Campillo N; Montero M; Esteve E; Herrera S; Benito N; Alvarez-Lerma F; Grau S; Horcajada JP
    BMC Infect Dis; 2017 Jan; 17(1):11. PubMed ID: 28056821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.